The FDA has unveiled three new draft guidance documents aimed at refining the 510(k) Program for medical devices. These documents, part of the FDA’s ongoing efforts to enhance the clarity and consistency of the 510(k) Program, emphasize the importance of selecting appropriate predicate devices, the use of clinical data, and setting evidentiary expectations for implant devices. As the regulatory landscape evolves, the significance of a robust Quality Management System (QMS) becomes even more paramount. A well-implemented QMS not only ensures compliance but also fosters a culture of continuous improvement and quality.

FDA Issues New Draft Guidance Documents to Strengthen the 510(k) Program for Medical Devices

The U.S. Food and Drug Administration (FDA) has recently issued three new draft guidance documents to improve the safety and effectiveness of medical devices that are marketed through the 510(k) Program. The 510(k) Program is a premarket review process that allows manufacturers to demonstrate that their new device is substantially equivalent to a legally marketed device, also known as a predicate device.

The FDA’s Center for Devices and Radiological Health (CDRH) has been working for over a decade to modernize and optimize the 510(k) Program, which is one of the most common pathways for bringing medical devices to the U.S. market. The new draft guidance documents are part of CDRH’s ongoing efforts to enhance the clarity, predictability, and consistency of the 510(k) Program, as well as to encourage innovation and promote patient safety.

2018 FDA Report Outlining Steps Taken to Strengthen the 510(k) Program and the 2019 Guidance on Safety and Performance Based Pathway:

The FDA’s 510(k) program is a process that allows medical device manufacturers to market their products in the U.S. by demonstrating that they are substantially equivalent to existing devices. However, the program has been criticized for being outdated, inconsistent, and lacking in transparency. In 2018, the FDA published a report with recommendations on how to modernize and improve the 510(k) program. Some of the main recommendations are:

  • Establishing a new alternative pathway for 510(k) clearance that would rely on objective performance criteria instead of predicate devices.
  • Promoting the use of more recent and relevant predicate devices by retiring older ones that do not reflect current standards of safety and effectiveness.
  • Enhancing the quality and consistency of 510(k) submissions and reviews by providing more guidance, training, and feedback to industry and FDA staff.
  • Increasing the transparency and accountability of the 510(k) program by making more information available to the public and stakeholders.

The report also outlines the benefits and challenges of implementing these recommendations, as well as the expected impact on public health and innovation. The report is part of the FDA’s ongoing efforts to ensure that the 510(k) program meets the needs of patients and health care providers in the 21st century.

In September 2019, then, the FDA’s Center for Devices and Radiological Health (CDRH) finalized guidance on the Safety and Performance Based Pathway, an alternative to the Traditional 510(k) Program. This pathway allows manufacturers of certain well-understood device types to demonstrate that a new device meets FDA-identified performance criteria, showing that the device is as safe and effective as a legally marketed device. This new, efficient pathway may incentivize the development of safer, more effective devices by allowing manufacturers to demonstrate their product’s superior performance to existing devices more readily. Since the issuance of the Safety and Performance Based Pathway final guidance, the FDA has published ten device-specific final guidance documents for devices with corresponding FDA-identified performance criteria, ranging from bone screws to magnetic resonance coils.

Summary of the Three New Draft Guidance Documents to Further Improve the 510(k) Process:

  • Best Practices for Selecting a Predicate Device: This guidance provides recommendations for manufacturers on how to choose a predicate device that meets or exceeds the expected safety and performance standards, or that does not have unresolved safety issues. The guidance also suggests that manufacturers describe how they used these best practices in their 510(k) submission and summary.
  • Recommendations for the Use of Clinical Data: This guidance clarifies when clinical data may be needed to support a 510(k) submission, especially when there are differences in the technological characteristics or risks between the new device and the predicate device. The guidance also provides examples of situations where clinical data may or may not be necessary.
  • Evidentiary Expectations for 510(k) Implant Devices: This guidance provides updated recommendations for manufacturers on how to design and conduct appropriate performance testing for 510(k) implant devices, as well as what information and labeling to include in their 510(k) submissions. The guidance also includes new recommendations for patient labeling and “implant ID cards.”


The FDA is seeking public comments on these draft guidance documents before finalizing them. The agency hopes that these guidance documents will help manufacturers provide the appropriate data and information to support their 510(k) submissions, and ultimately improve the quality and safety of medical devices for patients.

The FDA’s draft guidance documents are available on its website. For more information on the 510(k) Program and other medical device topics, please visit the FDA’s website.

Importance of a Robust Quality Management System (QMS):

A robust Quality Management System (QMS) that aligns with the requirements of 21 CFR 820 and ISO 13485 is paramount for medical device manufacturers. Such a QMS not only ensures compliance with stringent regulatory standards but also fosters a culture of continuous improvement, risk management, and patient safety. By adhering to these recognized standards, manufacturers can confidently navigate the complex medical device landscape, ensuring their products consistently meet the highest levels of quality and safety, thereby building trust with both regulators and end-users.  A robust QMS:

  1. Ensures Compliance: A well-implemented QMS ensures that a company consistently meets FDA regulations and other relevant standards. This reduces the risk of non-compliance and potential regulatory actions.
  2. Streamlines Documentation: A key component of a QMS is document control. This ensures that all necessary documents are maintained, updated, and easily accessible, which is crucial for a successful 510(k) submission.
  3. Risk Management: A QMS emphasizes risk management throughout the product lifecycle. By identifying and mitigating risks early, manufacturers can avoid costly delays and potential recalls in the future.
  4. Continuous Improvement: A QMS is not just about compliance; it’s about continuously improving processes and products. This can lead to better product quality, reduced costs, and increased customer satisfaction.
  5. Builds Trust: A robust QMS can build trust with regulators, stakeholders, and customers. It demonstrates a company’s commitment to quality and safety.
  6. Facilitates Communication: A QMS often emphasizes clear communication across different departments. This can be invaluable during the 510(k) submission process, where collaboration between R&D, regulatory affairs, quality assurance, and other teams is essential.

While the 510(k) submission process can be challenging, having a robust QMS in place can significantly ease the process. It ensures that manufacturers are always prepared, reduces the risk of non-compliance, and fosters a culture of quality and continuous improvement. Whether you are a startup going through the design and development phases on your first product and looking to understand the regulatory landscape to bring your product to market, or you’re a veteran medical device manufacturer looking to improve your QMS to improve your ability to meet regulatory requirements, improve design and development accuracy and efficiency, and reduce risk of rejection during the pre-market approval, we’ve got solutions to help.  Reach out to request a demo of our robust suite of QMS applications tailor-made to improve cross-functional communication, improve design and development and market approval processes, and better meet regulatory requirements. You can trial all our 20 applications at no cost and with no obligation during a 30-day proof-of-concept to see for yourself how we can help your organization to work intelligently.

The Core GRC Solution Set:

  • DocuQuest
  • PeopleQuest
  • AuditQuest
  • FMEAQuest
We use cookies to improve your experience on our site, and to keep it reliable and secure.
To find out more, please read our Privacy Policy.